Bluejay Diagnostics provided a corporate update for Q3 2026, highlighting the completion of enrollment for its SYMON-II clinical study and the establishment of an alternative manufacturing site ahead of schedule. The company reported a cash balance of $7.38 million and targets an FDA 510(k) submission for its Symphony IL-6 platform in the first half of 2027.
Bluejay Diagnostics reported a net loss of $6.26 million for the nine months ended September 30, 2026, compared to $5.42 million in the prior year period. The company strengthened its cash position to $7.38 million through private placements and warrant exercises, while continuing to invest heavily in research and development for its diagnostic platform.
Bluejay Diagnostics implemented a 1-for-4 reverse stock split of its common stock, effective November 3, 2026. The split reduces the number of outstanding shares from approximately 4.47 million to 1.12 million to maintain compliance with Nasdaq listing requirements. Trading will continue under the ticker 'BJDX' with a new CUSIP number.